From: The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer
Patient group | Parameters | P-value | HR | 95% CI | |
---|---|---|---|---|---|
 |  |  |  | Lower | Upper |
whole cohort | Cx26post | 0.303 | 0.450 | 0.098 | 2.055 |
 | ERpost | 0.050 | 2,739 | 0.999 | 7.504 |
 | Cx26post | 0.157 | 0.134 | 0.008 | 2.173 |
 | PRpost | 0.027 | 6.509 | 1.241 | 34.140 |
 | CPS EG | 0.967 | 0.000 | 0.000 | 1.381E26 |
EWGBSP TR2b | Cx46post | 0.790 | 4.400 | 0.844 | 22.950 |
 | PRpost | 0.115 | 3.809 | 0.722 | 20.111 |
Sataloff TB | Cx46post | 0.226 | 3.782 | 0.439 | 32.600 |
 | PRpost | 0.244 | 2.791 | 0.496 | 15.711 |
Miller-Payne G3 | Cx46post | 0.104 | 3.322 | 0.782 | 14.105 |
 | PRpost | 0.075 | 4.400 | 0.861 | 22.481 |